Citigroup
HEPA

Citigroup’s Hepion Pharmaceuticals HEPA Stock Holding History

Citigroup’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Hold
0
– – – 5736
2024
Q4 		– Hold
0
– – – 5885
2022
Q2 		– Sell
-4
Closed -$5K – 6399
2022
Q1 		$5K Buy
+4
New +$4.42K ﹤0.01% 5815
2016
Q4 		– Hold
0
– – – 7236
2016
Q3 		– Hold
0
– – – 7113
2016
Q2 		– Hold
0
– – – 7201
2016
Q1 		– Hold
0
– – – 7568
2015
Q4 		– Hold
0
– – – 7675
2015
Q3 		– Hold
0
– – – 7507
2015
Q2 		– Hold
0
– – – 7606
2015
Q1 		– Hold
0
– – – 7281

Other funds holding HEPA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's HEPA Position: Q1 2025 in Review

Citigroup held its Hepion Pharmaceuticals (HEPA) position steady in Q1 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5736.

Citigroup first reported a position in HEPA in Q1 2022 and has held it in 1 quarter since. The position peaked at $5K in Q1 2022. 16 funds tracked by Wall St. Rank hold HEPA as of Q1 2025.

  • Citigroup held 0 shares of Hepion Pharmaceuticals worth $0 as of Q1 2025.
  • Citigroup left its Hepion Pharmaceuticals share count unchanged in Q1 2025.
  • Hepion Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2025, its #5736 holding.
  • Citigroup first reported a position in Hepion Pharmaceuticals in Q1 2022 and has held it in 1 quarter since.
  • Citigroup's Hepion Pharmaceuticals position peaked at $5K in Q1 2022.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.